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Atherosclerotic Plaque Composition and Occurrence of Restenosis
After Carotid Endarterectomy
Hellings WE, Moll FL, De Vries JP, et al. JAMA 2008;299:547-54.
Conclusion: Lipid-rich inflammatory plaques are associated with a
reduced risk of restenosis after carotid endarterectomy.
Summary:Both clinical and angiographic criteria have been used to try
to determine the risk of restenosis after a vascular intervention. The authors
of this study evaluated the composition of the atherosclerotic plaque at the
intervention site in terms of plaque features that may be related to carotid
restenosis after carotid endarterectomy. There were 500 patients prospec-
tively followed up between April 1, 2002, and March 14, 2006. Patients
were assessed for carotid artery restenosis as measured by duplex ultrasound
imaging 1 year after intervention. A 50% stenosis was defined as a peak
systolic velocity of 125 cm/s and a 70% stenosis was defined as a peak
systolic velocity of 230 cm/s. Carotid restenosis after carotid endarterec-
tomy was determined with predefined histologic plaque characteristics.
These included macrophage and smooth muscle cell infiltration, collagen,
calcification, interplaque hemorrhage, luminal thrombus, and lipid core size.
Comparisons were determined using multivariate logistic regression analysis
and were adjusted for clinical characteristics.
At 1 year, 85 patients (17%) had developed 50% carotid restenosis,
and 40 (8%) developed 70% restenosis. Histologic examination of the
plaque revealed that increased macrophage infiltration (n  286) had a
lower risk of 50% restenosis than plaques with no or minor macrophage
infiltration (n  215; 11.5% vs 24.3%; adjusted odds ratio [OR], 0.43; 95%
confidence interval [CI], 0.26-0.72). Patients with higher macrophage
infiltration also had a lower risk of developing 70% restenosis (4.5% vs
12.6%; adjusted OR, 0.36; 95% CI, 0.17-0.74). The 177 patients whose
plaque had a lipid core that was40% of plaque volume also had a lower risk
of 50% restenosis than the 94 patients with a lipid core size of 10%
(11.3% vs 25.5%; adjusted OR, 0.40; 95% CI, 0.19-0.81). A large lipid core
also had a lower risk of developing70% restenosis (5.6% vs 14.9%; adjusted
OR, 0.42; 95% CI, 0.17-1.04).
Comment: Many of the findings of this study are unexpected. Plaque
characteristics of inflammation and higher lipid content, commonly thought
to be associated with more dangerous plaques were, in this study, associated
with lower rates of restenosis after carotid endarterectomy. Their other
findings also seem in opposition to previous studies or prevailing opinion.
For example, an incidence of 21% of 50% restenosis with Dacron patch
angioplasty at 1 year is higher than usually reported. Also, vein and Dacron
patches are not generally regarded as having much difference in their ability
to prevent restenosis after carotid endarterectomy, but this study found vein
patches were more much effective in preventing restenosis than Dacron
patches. The high incidence of restenosis in this study may be explained by
the duplex characteristics for defining 50% and 70% internal carotid
artery stenosis. The duplex parameters used are likely to be more sensitive
than specific, thereby artificially elevating the incidence of carotid restenosis
after carotid endarterectomy.
Anemia as an Independent Predictor of Perioperative and Long-term
Cardiovascular Outcome in Patients Scheduled for Elective Vascular
Surgery
DunkelgrunM,Hoeks SE,WeltenGM, et al. Am JCardiol 2008;101:1196-
200.
Conclusion: Preoperative anemia predicts an increased risk of 30-day
and 5-year cardiac events, independent of underlying heart and renal disease.
Summary: The authors sought to determine whether anemia was an
independent risk factor for adverse cardiac outcome in patients undergoing
elective vascular surgery. This was a retrospective study where 1363 patients
with known or suspected coronary artery disease were referred for testing
before they underwent scheduled elective, noncardiac, open vascular sur-
gery. The study took place at Erasmus Medical Center in the Netherlands
from 1990 to August 2006. Preoperative testing included standard labora-
tory chemistries and complete blood counts as well as echocardiography and
assessment of baseline clinical characteristics. A total of 152 patients were
treated at another hospital and were excluded, leaving 1211 patients for
analysis (77% men, 68  11 years of age). Anemia was defined as a serum
hemoglobin level 13 g/dL for men and 12 g/dL for women. Anemia
levels were divided into tertiles: mild (men, 12.2-13.0 g/dL; women,
11.2-12.0 g/dL), moderate (men, 11.0-12.1 g/dL; women, 10.2-11.1
g/dL), and severe (men, 7.2-11.0 g/dL; women, 7.5-10.1 g/dL). Out-
come measures were 30-day and 5-year major adverse cardiac events
(MACE; myocardial infarction or cardiac death).
Analysis was performed with multivariable logistic and Cox regression
techniques adjusting for cardiac risk factors, including heart failure and renal
disease. Data are presented as hazard ratios (HRs), with 95% confidence
intervals. There were 74 patients (6%) who had a 30-day MACE, and 199
patients (17%) had a 5-year MACE event. Anemia was detected preopera-
tively in 399 patients (33%): anemia was mild 133, moderate in 133, and
severe in 133. Renal dysfunction, diabetes, and heart failure all were associ-
ated with anemia. After adjusting for clinical risk factors, 30-day HRs for a
MACE per anemia group were 1.8 for mild (0.8-4.1), 2.3 for moderate
(1.1-5.4), and 4.7 for severe (2.6-10.9) anemia. The 5-year HRs for a
MACE per anemia group were 2.4 for mild (1.5-4.2), 3.6 for moderate
(2.4-5.6), and 6.1 for severe (4.1-9.1) anemia.
Comment: Things are getting more complicated with respect to
anemia in the perioperative period. On the one hand, we have information
indicating transfusion probably increases surgical site infection and periop-
erative and late death. Conversely, studies such as this indicate anemia is a
marker for early and late postoperative MACE. There is probably some
correct information in both types of studies. Anemia is detrimental around
the time of a vascular operation, but correcting it postoperatively may not
help and perhaps makes things worse. There are likely many unrecognized
confounding variables. Vascular surgeons should understand their anemic
patients are at higher risk and that risk is not likely to be reduced by a liberal
postoperative transfusion policy. Perhaps this makes it even more important
in such patients to optimize perioperative -blockers, antiplatelet, and statin
medications.
Modeling the Long-term Cost-Effectiveness of Endovascular or Open
Repair for Abdominal Aortic Aneurysm
Epstein DM, Sculpher MJ, Manca A, et al. Br J Surg 2008;95:183-90.
Conclusion: Endovascular aneurysm repair (EVAR) is not cost-
effective.
Summary: EVAR has been shown in recent randomized trials to have
a 3% aneurysm-related survival benefit compared with open surgery in
patients who are suitable for both open and EVAR of an abdominal aortic
aneurysm (AAA). EVAR has a high graft-related cost, a need for long-term
follow-up, and an uncertain long-term outcome. This study used a decision
model to estimate lifetime costs and quality-adjusted life-years with EVAR
and open AAA repair in men aged 74 years. Risk of death from aneurysm-
related causes, other cardiovascular causes, and noncardiovascular causes, as
well as nonfatal cardiovascular events and reinterventions, were incorporated
into the model. The patients were assumed to be 74 years old because this
was the mean age of participants in EVAR-1. The measure of health benefit
was expected quality-adjusted survival duration. All costs were measured in
United Kingdom pounds based on 2004 pricing. Both health benefits and
costs in future years were discounted at a rate of 3.5% per year. Most of the
data used in the modeling was from the EVAR-1 trial, but it was supple-
mented by data from population tables, registries, and the Dutch Random-
ised Endovascular Aneurysm Management (DREAM) trial. Because both
EVAR-1 and the DREAM trial found no late survival benefit, an increased
risk of cardiovascular mortality was assumed in the EVAR-treated patients.
This risk was varied in sensitivity analysis in the model.
Using base-case (primary assumptions), EVAR was found to cost
£3800 (95% confidence interval [CI], £2400-£5200) more per patient than
open repair. EVAR also produced fewer lifetime quality-adjusted life-years
(mean, 0.020; 95% CI, 0.189 to 0.165) than open repair. The results
remain sensitive to alternative model assumptions.
Comment: The data indicate, at least from the perspective of the
National Health Service in the United Kingdom, that EVAR is unlikely to be
cost-effective. The cost of EVAR is largely driven by the cost of the devices,
which are ultimately, as the authors pointed out, under the control of the
manufacturers. When all factors are considered, EVAR is not proving to be
the “home run” that it was touted to be. At some point the cost of increasing
medical technology is going to prove to be prohibitive. Both vascular
surgeons and industry may be wise to be proactive in controlling costs of
EVAR.
The Effect of Lower Targets for Blood Pressure and LDL Cholesterol
on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard BV, Roman MJ, Devereux RB, et al. JAMA 2008;299:1678-89.
Conclusion: Aggressive reduction of low-density lipoprotein choles-
terol (LDL-C) and systolic blood pressure (SBP) can result in regression of
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